GlassScriptPhysician profile
Walid John Haddad
NPI 1487600060
$3,731.41
in general payments reported to CMS, 2019-2025
24 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $193 · 2021: $426 · 2022: $394 · 2023: $510 · 2024: $1,192 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,384.15 | 2021-2024 | Micra, Linq II, Selectsite |
| Medtronic Vascular, INC. | $531.54 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.37 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $215.91 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.77 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $177.95 | 2021-2024 | Verquvo, Belsomra |
| Boston Scientific Corporation | $168.36 | 2025 | Cds Broad Portfolio Offering, Bodyguardian, Cds - Mct/Cem Monitoring |
| Astrazeneca Pharmaceuticals LP | $123.06 | 2019-2022 | |
| Philips North America LLC | $107.19 | 2023-2024 | (Ck4) Mcot |
| E.R. Squibb & Sons, L.L.C. | $105.41 | 2023-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $98.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Irhythm Technologies, INC. | $89.59 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Daiichi Sankyo INC. | $51.92 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $38.68 | 2024 | Onpattro |
| Amarin Pharma, INC. | $31.93 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.90 | 2019 | |
| Pfizer INC. | $27.56 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $20.77 | 2021 | |
| Bardy Diagnostics, INC. | $18.63 | 2020 | |
| Edwards Lifesciences Corporation | $16.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.41 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.20 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2021 | |
| Amgen INC. | $14.35 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.